Patrick W. McLaughlin, MD

Patrick W. McLaughlin, MD

University of Michigan Radiation Oncology Associates

Novi, Michigan

Bill McLaughlin, MD is the Medical Director of Radiation Oncology and the Medical Director of the Healing Arts Program at Providence. Dr. McLaughlin is a board-certified radiation oncologist with a special interest in prostate cancer. He is a professor of Radiation Oncology at the University of Michigan. Dr. McLaughlin is a member of American Society for Therapeutic Radiology and Oncology (ASTRO) and American Brachytherapy Society (ABS). Dr. McLaughlin pioneered MRI based treatment planning for prostate implants and external beam therapy. Incorporating MRI imaging lead to the development of vessel-sparing radiation analogous to nerve-sparing prostatectomy. MRI based evaluation post implant has improved the accuracy of implant checking and improved the quality of prostate implants. These techniques have vastly improved the quality of life for men with prostate cancer. The results of this research were published in the International Journal of Radiation Oncology, Biology, and Physics. Dr. McLaughlin participated in the design of the Assarian Cancer Center, featuring an integrated healing arts center and program to improve patient and family support at all stages of the cancer experience.

Articles by Patrick W. McLaughlin, MD

Hormone Therapy in High Risk Prostate Cancer

Patrick W. McLaughlin, MD, discusses balancing the therapeutic effects of androgen deprivation therapy (ADT) with the impact of quality of life (QOL). He examines the best timing and radiotherapy regimen combination to pair with ADT, as well as properly assessing individual patients’ risk factors and disease severity when choosing treatment options.

Read More

The Staggering Benefit of PSA Screening in Potentially Lethal Prostate Cancer

Patrick W. McLaughlin, MD, discusses the limitations of evidence that provide the basis for the United States Preventive Services Task Force’s (USPSTF’s) negative gradings for PSA screening. He argues that in the modern era, with the currently-available curative therapy for most lethal prostate cancers, intensive screening can allow early enough detection to provide patients opportunities for a cure. 

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -